Completed PHASE3 INTERVENTIONAL 3-arm NCT01459809

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients (RECOMMEND)

A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes

Sponsor: Sanofi

Conditions Diabetes Mellitus, Type 2

Interventions GLIMEPIRIDE METFORMIN

Updated 7 times since 2017 Last updated: Jan 19, 2015 Started: Feb 29, 2012 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Sanofi leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Algeries, Algeria , Antalya, Turkey (Türkiye) , Bangalore, India , Beirut, Lebanon , Cairo, Egypt , Chouf, Lebanon , Dubai, United Arab Emirates , Durban, South Africa , El Espinal, Colombia and 26 more locations